NCT03264703View on ClinicalTrials.gov

Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World

CompletedOBSERVATIONAL
Enrollment

212

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

July 17, 2019

Study Completion Date

July 17, 2019

Conditions
Arthritis, Rheumatoid
Trial Locations (15)

Unknown

Eisai Trial Site # 1, Ilsan

Eisai Trial Site # 1, Busan

Eisai Trial Site # 2, Busan

Eisai Trial Site # 3, Busan

Eisai Trial Site # 4, Busan

Eisai Trial Site # 1, Daegu

Eisai Trial Site # 2, Daegu

Eisai Trial Site # 1, Seoul

Eisai Trial Site # 2, Seoul

Eisai Trial Site # 3, Seoul

Eisai Trial Site # 4, Seoul

Eisai Trial Site # 5, Seoul

Eisai Trial Site # 6, Seoul

Eisai Trial Site # 7, Seoul

Eisai Trial Site # 8, Seoul

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT03264703 - Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World | Biotech Hunter | Biotech Hunter